Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001641172-25-021793
Filing Date
2025-07-31
Accepted
2025-07-31 19:46:45
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 22234
2 EX-99.1 ex99-1.htm EX-99.1 18317
  Complete submission text file 0001641172-25-021793.txt   42371
Mailing Address 4851 TAMIAMI TRAIL NORTH SUITE 200 NAPLES FL 34103
Business Address 4851 TAMIAMI TRAIL NORTH SUITE 200 NAPLES FL 34103 (646) 491 9132
CONDUIT PHARMACEUTICALS INC. (Subject) CIK: 0001896212 (see all company filings)

EIN.: 873272543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-93313 | Film No.: 251173318
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address WILLOW HOUSE, CRICKET SQUARE PO BOX 709 GRAND CAYMAN E9 KY1 - 1107
Business Address WILLOW HOUSE, CRICKET SQUARE PO BOX 709 GRAND CAYMAN E9 KY1 - 1107 44 7766 766766
Corvus Capital Ltd. (Filed by) CIK: 0001990829 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9
Type: SCHEDULE 13D/A